AMSBIO: Cell Culture Medium for Clinical Research

AMSBIO announces the launch of StemFit® Basic03 clinical grade stem cell culture for regenerative medicine.

Provided as a animal-origin free, ready to use media for cell therapy applications, StemFit® AK03N which is the Japanese version of Basic03 has already been accepted by Pharmaceuticals and Medical Devices Agency, Japan (PMDA) for retinal regenerative medicine clinical trials using human induced pluripotent stem cells (hiPSCs).

In an independent study**, media of different formulations were compared with StemFit® Basic03 for culturing iPS cells. The resultant research data showed, iPS cells cultured with StemFit® Basic03 offered higher cell proliferation, lower lactate accumulation and demonstrated better homogeneity of gene expression compared with iPS cells cultured with 4 other media.

Completely free of animal- and human-derived components StemFit® Basic03 is proven to provide highly stable and reproducible culture condition for Induced Pluripotent Stem and Embryonic Stem cells under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture. StemFit® Basic03 combines high colony forming efficiency with lower than standard media volume consumption to offer cost effective colony expansion when compared to leading competitors.

For a copy of a poster describing this study please visit www.amsbio.com/presentation/stemfit-catapult-poster.pdf. For further information on StemFit® Basic03 please visit http://www.amsbio.com/Feeder-Free-Stem-Cell-Culture.aspx or contact the company on +44-1235-828200/ +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

** The study was undertaken by the Cell and Gene Therapy Catapult (CGT Catapult) - an independent centre of excellence set-up to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialization.

Worldwide HQ 

AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon

Oxon OX14 4SE

UK
Tel:+44-1235-828200
Fax:+44-1235-820482
Email:info@amsbio.com 
Web www.amsbio.com

 

North American HQ

 

AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel:+1.617.945.5033 
Tel:+1.800.987.0985 (toll free)
Email:info@amsbio.com 
Web www.amsbio.com